Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 220-292-5 | CAS number: 2705-87-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The NOAEL for oral repeated dose toxicity was >214 mg/kg bw/day in a chronic study in the rat.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- chronic toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with national standard methods with acceptable restrictions
- Remarks:
- Pre-GLP, pre-OECD TG study with sufficient detail in documentation
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 452 (Chronic Toxicity Studies)
- Deviations:
- not specified
- Principles of method if other than guideline:
- The study was conducted prior to the publication of OECD TGs. The compound was fed in the diet. Fresh diets were made and distributed weekly for a period of 1 year.
- GLP compliance:
- no
- Limit test:
- yes
- Species:
- rat
- Strain:
- Osborne-Mendel
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: not reported
- Age at study initiation: weaning
- Weight at study initiation: not reported
- Fasting period before study: not reported
- Housing: individually in wire cages
- Diet (e.g. ad libitum): ad libitum
- Water (e.g. ad libitum): ad libitum
- Acclimation period: not reported
ENVIRONMENTAL CONDITIONS
- not reported - Route of administration:
- oral: feed
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
DIET PREPARATION
- Rate of preparation of diet (frequency): weekly
- Mixing appropriate amounts with (Type of food): not reported
- Storage temperature of food: not reported - Analytical verification of doses or concentrations:
- no
- Duration of treatment / exposure:
- 1 year
- Frequency of treatment:
- continuous
- Dose / conc.:
- 2 000 ppm
- Remarks:
- Basis:
nominal in diet - No. of animals per sex per dose:
- 5
- Control animals:
- yes, plain diet
- Details on study design:
- - Dose selection rationale: not reported
- Positive control:
- No
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: No data
DETAILED CLINICAL OBSERVATIONS: No data
BODY WEIGHT: Yes
- Time schedule for examinations: weekly
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: No data
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No data
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No data
OPHTHALMOSCOPIC EXAMINATION: No data
HAEMATOLOGY: Yes
- Time schedule for collection of blood: at 3, 6, 12 and 22 months
- Anaesthetic used for blood collection: No data
- Animals fasted: No data
- How many animals: No data
- The following parameters were examined: white cell counts, red cell counts, haemoglobins and haematocrits
CLINICAL CHEMISTRY: No data
URINALYSIS: No data
NEUROBEHAVIOURAL EXAMINATION: No data - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
HISTOPATHOLOGY: Yes - Statistics:
- No data
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not specified
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- not specified
- Urinalysis findings:
- not specified
- Behaviour (functional findings):
- not specified
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- not specified
- Details on results:
- CLINICAL SIGNS AND MORTALITY: no effects
BODY WEIGHT AND WEIGHT GAIN: no effects
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study): no effects
FOOD EFFICIENCY: no data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): no data
OPHTHALMOSCOPIC EXAMINATION: no data
HAEMATOLOGY: no effects
CLINICAL CHEMISTRY: no data
URINALYSIS: no data
NEUROBEHAVIOUR: no data
ORGAN WEIGHTS: no effects
GROSS PATHOLOGY: no effects
HISTOPATHOLOGY: NON-NEOPLASTIC: no effects - Dose descriptor:
- NOEL
- Effect level:
- > 2 500 ppm
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: based on 30 g/day food consumption and 350 g/rat body weight
- Key result
- Dose descriptor:
- NOEL
- Effect level:
- > 214 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: based on 30 g/day food consumption and 350 g/rat body weight
- Key result
- Critical effects observed:
- no
- Conclusions:
- In 1-year feeding study no effects on the test item was observed up to 2500 ppm (mg/kg diet) or > 214 mg/kg bw/day.
- Executive summary:
Groups of 5 weanling Osborne-Mendel rats per sex were housed individually in wire cages, and were allowed food and water ad libitum. The animals were administered the test material at 2500 ppm in the diet for 1 year, and the diet was prepared weekly. Weight, food intake and general condition were recorded weekly. Hematological examinations included white cell counts, red cell counts, hemoglobin and hematocrits and these were conducted at the termination of the study. On completion of the study, all surviving animals were sacrificed and examined macroscopically. Organ weights were recorded and tissues were preserved for histopathologic examination. Detailed microscopic examinations were done on 6 or 8 animals evenly divided by sex. No effects on the test item were observed up to 2500 ppm (mg/kg diet) or > 214 mg/kg bw/day.
Reference
Endpoint conclusion
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 214 mg/kg bw/day
- Study duration:
- chronic
- Species:
- rat
- Quality of whole database:
- Pre-GLP, pre-OECD TG study, but with sufficient detail in documentation.
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
The following animal data on repeated dose toxicity of allyl 3-cyclohexylpropionate and allyl heptanoate are available
Identifier of the study | Klimisch score and relevance | Test method and animal species | Result | Effect |
Leuschner 2010 | K1, supporting, conducted with allyl heptanoate (read across) | Repeated dose toxicity: | NOAEL: | Changes in liver (yellow-stained discolouration, chronic inflammation, oval cell hyperplasia, pigment deposition |
oral (gavage) | 35 mg/kg bw/day | |||
28 days, rat |
| |||
Hagan 1967a | K2, key | Repeated dose toxicity: | NOEL: | No effect |
oral (feeding), | > 2500 ppm (mg/kg diet) | |||
1 year, rat |
| |||
Hagan 1967b | K2, supporting | Repeated dose toxicity: | NOEL: | No effect |
oral (feeding), | > 1000 ppm (mg/kg diet) | |||
27-28 weeks, rat |
|
Repeat dose toxicity, oral:
Allyl heptanoate produced adverse effects in a 28-day oral repeated dose toxicity study in the rat at a dose of 100 mg/kg bw/day, corresponding to an oral dose of allyl 3-cyclohexylpropionate of 116.7 mg/kg bw/day. The NOAEL in the key study was 30 mg/kg bw/day (35 mg/kg bw/day for allyl 3-cyclohexylpropionate).
In a reliable key feeding study (Hagan 1967a) allyl 3-cyclohexylpropionate was administered orally via feed to Osborne-Mendel rats (5/gender/dose) for 1 year, at concentrations of 0 (control) and 2500 ppm. No adverse effects were observed in this study.
In the supporting study (Hagan 1967b) rats were exposed orally via feed at a dose level of 1000 ppm allyl 3-cyclohexylpropionate during 27-28 weeks. No adverse effects were observed.
The NOAEL from the chronic feeding study assigned as key study (Hagan 1967a) is chosen as the starting point for DNEL derivation since it reflects most accurately the real exposure scenario in the occupational and general population. Administration of the allyl esters by gavage leads to toxic effects because glutathione (GHS) pathway is saturated rapidly and the presence of acrolein excess causes adverse effects to liver via macromolecular adduct formation, etc. From the available data we assume, that administration of the allyl esters by feeding allows slow acrolein formation and elimination via GHS pathway without this saturation and without causing toxic effects to liver.
Justification for selection of repeated dose toxicity via oral route - systemic effects endpoint:
The oral repeated dose toxicity of the substance was characeterised from a valid chronic oral toxicity study conducted with allyl 3-cyclohexylpropionate. The NOAEL in the study was >214 mg/kg bw/day.
Justification for classification or non-classification
Classification, Labelling, and Packaging Regulation (EC) No 1272/2008
The available studies are considered reliable for this assessment.
Repeated dose toxicity, oral:
Based on the above stated assessment of the specific target organ toxicity potential after repeated oral exposure of allyl 3-cyclohexylpropionate, the compound does not need to be classified according to Regulation (EC) No 1272/2008 of the European Parliament and of the Council No 1272/2008 (CLP), as amended for the 17th time in Regulation (EU) 2021/849) as implementation of UN-GHS in the EU.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.